Aeterna Zentaris Inc. Common Stock (NASDAQ: AEZS)
Company Name:Aeterna Zentaris Inc. Common Stock
Stock Symbol:NASDAQ: AEZS
Class Period Start:08/30/2011
Class Period End (inclusive):11/06/2014
According to the law firm press release, this case alleges that the defendants made materially false or misleading statements with respect to the safety and efficacy of the Company's drug Macrilen™. A November 6, 2014, press release by the Company brought these facts to light by announcing that the FDA had issued a Complete Response Letter refusing to approve the Company's New Drug Application because of "the lack of complete and verifiable source data for determining whether patients were accurately diagnosed with AGHD.